Phase 1/2 clinical study of humanized anti-bcma car t cells in relapsed/refractory multiple myeloma (MM)
Ended Project Grant Awarded Last action
- Award ID
- R44CA221432
- Recipient
-
Cartesian Therapeutics Inc. UEI PXGLS86SY6B1
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,952,904
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Funding
-
- $2,964,678.00 Federal
- $988,226.00 Non-federal
- Place of performance
- Maryland, USA
Award details come from USAspending.gov.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $988,226 | $0 | |
| Amendment | $988,226 | $988,226 | |
| Original award | $988,226 | $0 |
Quick answers
Who received award R44CA221432?
R44CA221432 was awarded to Cartesian Therapeutics Inc. by National Cancer Institute (National Institutes of Health) on August 1, 2018.
How much is award R44CA221432 worth?
$3,952,904 has been obligated on R44CA221432: $2,964,678 in federal funding and $988,226 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award